Heat shock proteins in cancer: targeting the 'chaperones'

被引:1
|
作者
Nahleh, Z. [1 ]
Tfayli, A. [2 ]
Najm, A. [3 ]
El Sayed, A. [4 ]
Nahle, Z. [5 ]
机构
[1] TTUHSC Paul L Foster Sch Med, Dept Internal Med, Div Hematol Oncol, El Paso, TX 79905 USA
[2] Amer Univ Beirut, Med Ctr, Beirut, Lebanon
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Mem Med Ctr, Las Cruces, NM 88011 USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA
关键词
HSP90 MOLECULAR CHAPERONE; POTENT ANTITUMOR-ACTIVITY; HEAT-SHOCK-PROTEIN-90; INHIBITOR; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; IN-VIVO; STRESS; RESISTANCE; EXPRESSION; HSP70;
D O I
10.4155/FMC.12.50
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Heat shock proteins (Hsps) are highly conserved proteins working as molecular chaperones for several cellular proteins essential for normal cell viability and growth, and have numerous cytoprotective roles. The expression of Hsps is induced in response to a wide variety of physiological and environmental stress insults, including anticancer chemotherapy, thus allowing the cell to survive lethal conditions. Cancer cells experience high levels of proteotoxic stress and rely upon stress-response pathways for survival and proliferation, thereby becoming dependent on proteins such as stress-inducible Hsps. Owing to the implication of Hsps in cancer, Hsp inhibition has recently emerged as an interesting potential anticancer strategy. Many natural and synthetic Hsp inhibitors molecular compounds are in development and many are being evaluated as potential cancer therapies. One of the Hsps in particular, Hsp90, has several client proteins and is emerging as a particularly exciting cancer target due to the prospect of simultaneously inhibiting chaperoning of numerous oncogenic proteins. This review describes the function of Hsps focusing on current efforts in exploiting the attributes of Hsps as potential targets for anticancer therapy.
引用
收藏
页码:927 / 935
页数:9
相关论文
共 50 条
  • [41] HEAT-SHOCK PROTEINS AND MOLECULAR CHAPERONES - IMPLICATIONS FOR ADAPTIVE RESPONSES IN THE SKIN
    MAYTIN, EV
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 104 (04) : 448 - 455
  • [42] ROLE OF CHAPERONES IN PROTEIN FOLDING-GROE HEAT-SHOCK PROTEINS
    GATENBY, AA
    DONALDSON, GK
    VANDERVIES, SM
    LORIMER, GH
    VIITANEN, PV
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1991, 202 : 116 - BIOT
  • [43] Small heat shock proteins operate as molecular chaperones in the mitochondrial intermembrane space
    Elias Adriaenssens
    Bob Asselbergh
    Pablo Rivera-Mejías
    Sven Bervoets
    Leen Vendredy
    Vicky De Winter
    Katrien Spaas
    Riet de Rycke
    Gert van Isterdael
    Francis Impens
    Thomas Langer
    Vincent Timmerman
    Nature Cell Biology, 2023, 25 : 467 - 480
  • [44] HEAT-SHOCK PROTEINS AND MOLECULAR CHAPERONES - IMPLICATIONS FOR PATHOGENESIS, DIAGNOSTICS, AND THERAPEUTICS
    MACARIO, AJL
    INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1995, 25 (02): : 59 - 70
  • [45] TorsinA and heat shock proteins act as molecular chaperones:: suppression of α-synuclein aggregation
    McLean, PJ
    Kawamata, H
    Shariff, S
    Hewett, J
    Sharma, N
    Ueda, K
    Breakefield, XO
    Hyman, BT
    JOURNAL OF NEUROCHEMISTRY, 2002, 83 (04) : 846 - 854
  • [47] Screening Molecular Chaperones Similar to Small Heat Shock Proteins in Schizosaccharomyces pombe
    Han, Jiyoung
    Kim, Kanghwa
    Lee, Songmi
    MYCOBIOLOGY, 2015, 43 (03) : 272 - 279
  • [48] The heat shock response and Chaperones/Heat shock proteins in brain tumors: Surface expression, release, and possible immune consequences
    Graner, Michael W.
    Cumming, R. Ian
    Bigner, Darell D.
    JOURNAL OF NEUROSCIENCE, 2007, 27 (42): : 11214 - 11227
  • [49] Targeting heat shock proteins to modulate α-synuclein toxicity
    Jones, Daryl Rhys
    Moussaud, Simon
    McLean, Pamela
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2014, 7 (01) : 33 - 51
  • [50] Recent Patents on Heat Shock Proteins Targeting Antibodies
    Fernandes, Joao C.
    Alves, Pedro
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2017, 12 (01) : 48 - 54